Sebastián GH (@sebstngh) 's Twitter Profile
Sebastián GH

@sebstngh

HPB Surgeon / SurgOnc. Tweets a título personal. No disclosures.

ID: 198389804

calendar_today04-10-2010 04:45:26

1,1K Tweet

295 Followers

866 Following

Japanese Society of HBP Surgery (@jshbps) 's Twitter Profile Photo

👇Don't miss this early view paper from #JHBPS 🇯🇵439 cases of hepatectomy (hep) for #CRLM were assessed in 3 groups; surgery alone, pre-hep chemo, post-hep chemo by #IPTW 💡post-hep chemo (but not pre-hep) prolong RFS of #CRLM than surgery alone #jshbps onlinelibrary.wiley.com/doi/10.1002/jh…

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥 Atezolizumab + bevacizumab vs surveillance in resected or ablated high-risk HCC (IMbrave050) The Lancet doi.org/10.1016/S0140-… 👉First positive adjuvant study in HCC 🧐Practice changing? 👉Don’t miss our commentary in The Lancet ESMO - Eur. Oncology EASLnews ILCA #livertwitter

🔥 Atezolizumab + bevacizumab vs  surveillance in resected or ablated high-risk HCC (IMbrave050)
<a href="/TheLancet/">The Lancet</a> 
doi.org/10.1016/S0140-…
👉First positive adjuvant study in HCC
🧐Practice changing?
👉Don’t miss our commentary in <a href="/TheLancet/">The Lancet</a>
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/EASLnews/">EASLnews</a> <a href="/ILCAnews/">ILCA</a> #livertwitter
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥Neoadj. FOLFIRINOX vs gemcitabine-based RT for borderline resectable & resectable #PDAC #ESMO23 ✅ PREOPANC-2 phs III, 375 pts 👉62% completed FOLFIRINOX, 81% >4 cycles 👉 72% adj Gem 👉moS 21.9 vs 21.3 👉≥3 TEAEs 67% vs 60% 🧐 neoadj. CTx promising, but not yet there...

🔥Neoadj. FOLFIRINOX vs gemcitabine-based RT for borderline resectable &amp; resectable #PDAC #ESMO23
✅ PREOPANC-2 phs III, 375 pts
👉62% completed FOLFIRINOX, 81% &gt;4 cycles
👉 72% adj Gem
👉moS 21.9 vs 21.3
👉≥3 TEAEs 67% vs 60%
🧐 neoadj. CTx promising, but not yet there...
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥mFOLFOXIRI plus cetuximab vs mFOLFOXIRI plus bevacizumab in RAS/BRAF wild-type and left-sided mCRC #ESMO23 ✅ The DEEPER trial 👉ORR 72 vs 75% 👉DpR 47 vs 59% 👉mPFS 14.5 vs 11.9 mo 👉More benefit for Cetuxi in non-liver limited disease 🧐OS awaited, overall no convincing data

🔥mFOLFOXIRI plus cetuximab vs mFOLFOXIRI plus bevacizumab in RAS/BRAF wild-type and left-sided mCRC #ESMO23
✅ The DEEPER trial
👉ORR 72 vs 75%
👉DpR 47 vs 59%
👉mPFS 14.5 vs 11.9 mo
👉More benefit for Cetuxi in non-liver limited disease
🧐OS awaited, overall no convincing data
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥Pembrolizumab vs CTX in MSI mCRC #ESMO23 ✅5-year follow-up KEYNOTE-177 👉mPFS 8.2 vs 15.5 mo 👉DoR 10 vs 75.5 mo 👉5yr OS 54 vs 44% 🧐Durable & meaningful benefit for Pembro in MSI CRC, but some are not responding... ESMO - Eur. Oncology

🔥Pembrolizumab vs CTX in MSI mCRC #ESMO23
✅5-year follow-up KEYNOTE-177
👉mPFS 8.2 vs 15.5 mo
👉DoR 10 vs 75.5 mo
👉5yr OS 54 vs 44%
🧐Durable &amp; meaningful benefit for Pembro in MSI CRC, but some are not responding...
<a href="/myESMO/">ESMO - Eur. Oncology</a>
Sharlene Gill, MD, MPH, MBA, FASCO (@gillsharlene) 's Twitter Profile Photo

#ESMO23 #crcsm 📣LBA27 CAIRO5 🇳🇱 ph3 in unresectable CRLM 📌arm A/B: bev+triplet v doublet in R-sided and/or RAS/BRAFmut ⛔️PFS better (HR0.76), higher ORR & RO rate but no OS benefit ➡️ no benefit with triplets 📌 bev+doublet v pani+doublet in L-sided and RAS/BRAF wt ⛔️ no PFS

#ESMO23 #crcsm
📣LBA27 CAIRO5 🇳🇱
ph3 in unresectable CRLM 
📌arm A/B: bev+triplet v doublet in R-sided and/or RAS/BRAFmut
⛔️PFS better (HR0.76),  higher ORR &amp; RO rate but no OS benefit
➡️ no benefit with triplets

📌 bev+doublet v pani+doublet in L-sided and RAS/BRAF wt
⛔️ no PFS
Annals of Surgical Oncology (@annsurgoncol) 's Twitter Profile Photo

OCTOBER ISSUE: Analysis of the Extent of Liver Oncological Extended Resection for #IncidentalGallbladderCancer: How Much Is Too Much? #liverresection rdcu.be/dph9C Society of Surgical Oncology

OCTOBER ISSUE: Analysis of the Extent of Liver Oncological Extended Resection for #IncidentalGallbladderCancer: How Much Is Too Much? #liverresection rdcu.be/dph9C <a href="/SocSurgOnc/">Society of Surgical Oncology</a>
Andrea Maliachi (@andreamaliachi) 's Twitter Profile Photo

Si eres paciente en tratamiento oncológico o conoces a alguien con #cáncer: 👁️‼️❗️revisen las cédulas profesionales y certificaciones de sus médicos. 👉🏽 buholegal.com/general/ No hay quimioterapia que rescate una mala cirugía… Acudan con especialistas.

Clemente (@j_clmnte) 's Twitter Profile Photo

Esta columna de Manuel Vicent para despedir el año. Disfrutad esta noche con la familia y los amigos. El tiempo pasa volando.

Esta columna de Manuel Vicent para despedir el año. Disfrutad esta noche con la familia y los amigos. El tiempo pasa volando.